311 – 320 of 629
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10-mg in non-elderly patients: The GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden.
(
- Contribution to journal › Article
-
Mark
Estimated glomerular filtration rate is associated with major bleeding complications but not thromboembolic events, in anticoagulated patients taking warfarin.
(
- Contribution to journal › Article
-
Mark
Computer aided warfarin dosing in the Swedish national quality registry AuriculA - Algorithmic suggestions are performing better than manually changed doses
(
- Contribution to journal › Article
-
Mark
Dabigatran in clinical practice - One-year experience at Skåne University Hospital.
(
- Contribution to journal › Letter
-
Mark
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
(
- Contribution to journal › Article
-
Mark
Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation.
(
- Contribution to journal › Article
-
Mark
Intermediate- dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s
(
- Contribution to journal › Article
-
Mark
Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study
(
- Contribution to journal › Article